Prestige Consumer Healthcare Inc (PBH)

Over the past year, Prestige Consumer Healthcare's stock has experienced a decline of 22.8%, trading near its 52-week low. Recent events impacting the stock price include the company's third-quarter fiscal 2026 results, released on February 5, 2026, where they reported a slight miss on revenue and adjusted diluted earnings per share. A significant factor contributing to the revenue decline was ongoing supply constraints for its Clear Eyes brand. To address these supply issues, Prestige Consumer Healthcare has taken strategic actions, including bringing on two new third-party suppliers and acquiring Pillar5 Pharma. The company also installed a new high-speed production line in December 2025 to scale output. Despite the revenue miss, the company demonstrated strong free cash flow generation and reaffirmed its full-year target.

Prestige Consumer Healthcare's products address recurring consumer needs, but certain categories may experience seasonal fluctuations. For instance, cough and cold products typically see higher demand during colder months, while other products like motion sickness treatments or feminine care might have more consistent demand throughout the year. The company's broad distribution across various channels helps mitigate reliance on any single product or category.

Prestige Consumer Healthcare, Inc. specializes in the development, manufacturing, marketing, sales, and distribution of OTC health and personal care products. The company operates within the healthcare sector and is recognized as one of the largest independent providers of OTC healthcare products in North America. Prestige Consumer Healthcare's business model focuses on acquiring, developing, and marketing well-recognized brands, many of which hold leading positions in niche consumer health categories. Its product portfolio includes Women's Health, Pain Relief, Eye Care, Specialty Oral Care, Motion Sickness, Digestive Health, Sore Throat Treatments, Wart Removal, Lice Treatment, Diaper Rash, Earwax Remover, Pediatric Care, Sleep Aids, Nasal Saline Sprays/Washes and Oral Rehydration.

Prestige Consumer Healthcare primarily operates in North America, generating approximately 85% of its total revenue from the United States and Canada. The company also has a significant presence in Australia, New Zealand, and certain other international and Asian markets.

Prestige Consumer Healthcare maintains a strong brand reputation, built on a portfolio of trusted brands that have served consumers for generations. The company emphasizes product innovation and quality in the OTC healthcare category. In the past year, the company's reputation has been impacted by supply constraints related to its Clear Eyes brand, but the company is actively working to resolve these issues. The company's commitment to sustainability and corporate stewardship also contributes to its brand image.

Institutional investors are the dominant force in Prestige Consumer Healthcare's ownership, holding a substantial majority of the company's shares. Major institutional owners include BlackRock, Inc., The Vanguard Group, Inc., Ariel Investments, Llc, and State Street Global Advisors, Inc.. Individual stakeholders hold a smaller portion of the company's shares.